Mycophenolate mofetil (CellCept - Roche) is a new immunosuppressant indicated "in combination with cyclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants". Here we review mycophenolate mofetil and assess whether it offers any additional benefits to conventional therapy.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.